Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 10/20 | 0.36 |
| ▸ | CTSE | P14091 | 10/20 | 0.36 |
| ▸ | BACE1 | P56817 | 7/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dolastatin 15 SCHEMBL12377885 | 1.00 | CTSD (0.36) | CTSDCTSEBACE1MEN1KMT2A | |
| Dolastatin 15 SCHEMBL4357916 | 1.00 | CTSD (0.36) | CTSDCTSEBACE1MEN1KMT2A | |
| Dolastatin 15 SCHEMBL13542771 | 1.00 | CTSD (0.36) | CTSDCTSEBACE1MEN1KMT2A | |
| Dolastatin 15 SCHEMBL14363293 | 1.00 | CTSD (0.36) | CTSDCTSEBACE1MEN1KMT2A | |
| Dolastatin 15 SCHEMBL14389122 | 1.00 | CTSD (0.36) | CTSDCTSEBACE1MEN1KMT2A | |
| Dolastatin 15 SCHEMBL19570274 | 1.00 | CTSD (0.36) | CTSDCTSEBACE1MEN1KMT2A | |
| Dolastatin 15 SCHEMBL12361466 | 1.00 | CTSD (0.36) | CTSDCTSEBACE1MEN1KMT2A | |
| SCHEMBL16801885 | 0.94 | CTSD (0.36) | CTSDCTSEBACE1MEN1KMT2A | |
| SCHEMBL19302617 | 0.93 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL19302613 | 0.93 | MEN1 (0.38) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2039 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2026-04-02 | — | — | US | claimed |
| EP-4637829-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF OVARIAN CANCER | Cellis Sp. z o.o. ([Ltd.] (PL) | 2025-10-29 | — | — | EP | claimed |
| US-20250325717-A1 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-23 | — | — | US | claimed |
| US-20250313647-A1 | MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-09 | — | — | US | claimed |
| US-20250276084-A1 | HYDROPHILIC LINKERS AND CONJUGATES THEREOF | GLYKOS FINLAND OY (FI) | 2025-09-04 | — | — | US | claimed |
| US-12398172-B2 | Therapeutic oligonucleotides | CARIS SCIENCE, INC. (US) | 2025-08-26 | — | — | US | claimed |
| EP-4313156-B1 | DISULFIDE-BASED PRODRUG COMPOUNDS | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2025-08-06 | — | — | EP | claimed |
| EP-4587062-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | Cellis AG (CH) | 2025-07-23 | — | — | EP | claimed |
| CN-120192413-A | Antibody targeting FR alpha or antibody coupling drug and application thereof | 三优生物医药(上海)有限公司 | 2025-06-24 | — | — | CN | claimed |
| US-20250177546-A1 | ROR1-TARGETED BINDING MOLECULE AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2025-06-05 | — | — | US | claimed |
| WO-2002015700-A1 | PRODRUGS ACTIVATED BY PLASMIN AND THEIR USE IN CANCER CHEMOTHERAPY | COULTER PHARMACEUTICAL, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| EP-1049481-A4 | SYNTHETIC ANTINEOPLASTIC AGENTS DERIVED FROM DOLASTATIN 15 AND METHODS OF MAKING SAME | UNIV ARIZONA (US) | 2001-09-12 | — | — | EP | claimed |
| WO-2001024763-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING IMMUNOCONJUGATES AND CHEMOTHERAPEUTIC AGENTS | IMMUNOGEN, INC. (US) | 2001-04-12 | — | — | WO | claimed |
| EP-1049481-A2 | SYNTHETIC ANTINEOPLASTIC AGENTS DERIVED FROM DOLASTATIN 15 AND METHODS OF MAKING SAME | ARIZONA BOARD OF REGENTS (US) | 2000-11-08 | — | — | EP | claimed |
| EP-0842190-B1 | PROCESS FOR PRODUCING DOLASTATIN 15 AND INTERMEDIATES THEREOF | BASF AG (DE) | 1999-10-06 | — | — | EP | claimed |
| WO-1999015130-A2 | SYNTHETIC ANTINEOPLASTIC AGENTS DERIVED FROM DOLASTATIN 15 AND METHODS OF MAKING SAME | ARIZONA BOARD OF REGENTS, actingon behalf of ARIZ ONA STATE UNIVERSITY (US) | 1999-04-01 | — | — | WO | claimed |
| EP-0842190-A1 | PROCESS FOR PRODUCING DOLASTATIN 15 AND INTERMEDIATES THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 1998-05-20 | — | — | EP | claimed |
| WO-1997005162-A1 | PROCESS FOR PRODUCING DOLASTATIN 15 AND INTERMEDIATES THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 1997-02-13 | — | — | WO | claimed |
| US-5554725-A | Synthesis of dolastatin 15 | ARIZONA BOARD OF REGENTS ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 1996-09-10 | — | — | US | claimed |
| US-4879278-A | ANTINEOPLASTIC | ARIZONA BOARD OF REGENTS (US) | 1989-11-07 | — | — | US | claimed |